486
On 22 March 2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 440. The active ingredient is recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene for treatment of congenital alpha-1 antitrypsin deficiency.